Shin Nippon Biomedical Laboratories Ltd

Shin Nippon Biomedical Laboratories discloses a rudimentary process for checking that its policy-engagement activities match its climate strategy: it explains that "æ‹...å½"è€...が経済ç"£æ¥­çœã€ç'°å¢ƒçœãªã©ã®å®˜å...¬åºãŒä¸»å‚¬ã - ã¦ã„ã‚‹æ° - 候変動é - ¢é€£ã‚»ãƒŸãƒŠãƒ¼ãªã©ã«å‚åŠ ã - 、æƒ...å ±ã‚'収集だ- ています" and that the information gathered is "整理だ- た上で、適宜、ç'°å¢ƒå§"å"¡ä¼šã€SDGså§"å"¡ä¼šã«å ±å'Šã - 、å¿...要に応じてå½"社グルーム- ã®æ° - å€™å¤‰å‹•æˆ¦ç•¥ã«åæ˜ ". This indicates that climate-related external engagement is at least reviewed by internal bodies (the Environment Committee and SDGs Committee), suggesting some oversight of how such engagement aligns with the company's climate strategy. However, the disclosure does not identify any individual or board-level authority responsible for approving or monitoring lobbying positions, does not describe any systematic assessment of trade-association positions or other indirect lobbying, and the company admits "No, and we do not plan to have one in the next two years" when asked about committing to conduct engagement in line with the Paris Agreement. Overall, while there is a basic review mechanism, the company does not disclose a formal lobbying-governance framework, regular alignment reviews, or transparent criteria for managing either direct or indirect lobbying activities.